Chronic Lymphocytic Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Lymphocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-10-17Clinical Trial Update: Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [Phase 2]
Phase 2 trial evaluating peripheral stem cell transplantation with combination chemotherapy in low-grade non-Hodgkin's lymphoma or chronic l…
-
CLINICAL_TRIALS trial_result · 2019-10-11Clinical Trial Update: Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer [Phase 2]
Phase 2 clinical trial update on donor umbilical cord blood transplant for hematologic cancers; status completed with results posted.
-
FDA label_change · 2019-10-08FDA Approved: BENDEKA — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for Bendeka (bendamustine hydrochloride) by Teva Pharmaceuticals to update its labeling.
-
CLINICAL_TRIALS trial_result · 2019-10-01Clinical Trial Update: Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia [Phase 3]
Phase 3 clinical trial comparing obinutuzumab plus venetoclax versus obinutuzumab plus chlorambucil in chronic lymphocytic leukemia; the stu…
-
CLINICAL_TRIALS trial_result · 2019-09-25Clinical Trial Update: Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL) [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating fludarabine, bendamustine, and rituximab (FBR) for relapsed chronic lymphocytic leukemia has completed w…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-09-24Clinical Trial Update: An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) [Phase 2]
An open-label Phase 2 study evaluating the combination of Ofatumumab (Arzerra) with GSK2110183 in relapsed/refractory chronic lymphocytic le…
-
CLINICAL_TRIALS trial_result · 2019-09-19Clinical Trial Update: Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL [Phase 1]
Phase 1 trial evaluating dimethylfumarate in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma; study terminat…
-
CLINICAL_TRIALS trial_result · 2019-09-18Clinical Trial Update: Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients [Phase 2]
Phase 2 trial evaluating the combination of PCI-32765 (ibrutinib) and rituximab in high-risk chronic lymphocytic leukemia and small lymphocy…
-
CLINICAL_TRIALS trial_result · 2019-09-17Clinical Trial Update: Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL [Phase 2]
Phase 2 trial evaluating ofatumumab-based induction chemoimmunotherapy in previously untreated chronic lymphocytic leukemia/small lymphocyti…
-
CLINICAL_TRIALS research · 2019-09-06Clinical Trial Update: Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery
Clinical trial assessing electrophysiological biomarkers of chemotherapy-related cognitive impairment and recovery; study completed with pos…
-
CLINICAL_TRIALS trial_result · 2019-09-06Clinical Trial Update: Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) [Phase 2]
Phase 2 trial investigating sapacitabine with cyclophosphamide and rituximab for relapsed CLL/SLL with 11q deletion; study terminated with r…
-
CLINICAL_TRIALS trial_result · 2019-08-28Clinical Trial Update: An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study [Phase 1, Phase 2]
An extension study of idelalisib (GS-1101) in subjects who benefited from prior idelalisib therapy; study terminated with results posted in …
-
CLINICAL_TRIALS trial_result · 2019-08-26Clinical Trial Update: Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL [Phase 2]
Phase 2 clinical trial evaluating alternating thalidomide and lenalidomide therapy plus rituximab (ThRiL) as initial treatment for chronic l…
-
CLINICAL_TRIALS trial_result · 2019-08-20Clinical Trial Update: Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512) [Phase 3]
Extension study update for idelalisib in chronic lymphocytic leukemia participants from a prior phase 3 trial; study terminated with results…
-
CLINICAL_TRIALS trial_result · 2019-08-16Clinical Trial Update: A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment [Phase 2]
Phase 2 clinical trial evaluating obinutuzumab and chlorambucil (GC) chemotherapy for elderly chronic lymphocytic leukemia patients, with NG…
-
CLINICAL_TRIALS trial_result · 2019-08-14Clinical Trial Update: A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia [Phase 1, Phase 2]
Clinical trial update for dasatinib plus rituximab in relapsed/refractory chronic lymphocytic leukemia; study terminated with results posted…
-
CLINICAL_TRIALS trial_result · 2019-08-13Clinical Trial Update: Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia [Phase 2]
Phase 2 trial of buparlisib in relapsed/refractory chronic lymphocytic leukemia has completed with results posted.
-
FDA approval · 2019-07-23FDA Approved: RUXIENCE — Original Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved Ruxience (rituximab-pvvr) from Pfizer as a biosimilar to rituximab, under an original application; the approval covers multiple…
-
CLINICAL_TRIALS trial_result · 2019-07-11Clinical Trial Update: Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]
Phase 2 clinical trial evaluating fludarabine phosphate, radiation therapy, and rituximab followed by rituximab maintenance in high-risk chr…
-
EMA withdrawal · 2019-07-08EMA Withdrawn: Rituzena (previously Tuxella) (rituximab) — Celltrion Healthcare Hungary Kft.
EMA withdrew Rituzena (rituximab) from the market (formerly Tuxella), with the decision dated 28 January 2019.
-
CLINICAL_TRIALS trial_result · 2019-06-26Clinical Trial Update: Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL [Phase 2]
A phase 2 trial evaluating high-dose methylprednisone followed by ofatumumab and alemtuzumab in 17p deletion CLL/SLL has been terminated wit…
-
CLINICAL_TRIALS trial_result · 2019-06-13Clinical Trial Update: Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia [Phase 1, Phase 2]
Clinical trial update for alemtuzumab in chronic lymphocytic leukemia across Phase 1 and Phase 2 shows completed status.
-
CLINICAL_TRIALS trial_result · 2019-05-29Clinical Trial Update: Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia [Phase 2]
Phase 2 clinical trial evaluating autologous peripheral blood stem cell transplant followed by donor bone marrow transplant in high-risk B- …
-
FDA approval · 2019-05-23FDA Approved: TRUXIMA — Supplemental Application (Cephalon, Inc.)
FDA approved a supplemental application for TRUXIMA (rituximab-ABBS) submitted by Cephalon, Inc.
-
CLINICAL_TRIALS trial_result · 2019-05-23Clinical Trial Update: Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia [Phase 3]
Phase 3 trial comparing fludarabine versus chlorambucil as first-line therapy in older patients with previously untreated chronic lymphocyti…